Sigyn Therapeutics (OTCMKTS:SIGY) Issues Earnings Results

Sigyn Therapeutics (OTCMKTS:SIGY) released its quarterly earnings results on Tuesday. The company reported ($2.51) EPS for the quarter, Zacks reports.

Sigyn Therapeutics Stock Performance

Shares of SIGY stock remained flat at $4.15 on Tuesday. The firm’s 50-day moving average is $4.01 and its 200-day moving average is $4.34. Sigyn Therapeutics has a fifty-two week low of $3.15 and a fifty-two week high of $6.34.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats.